Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joyce M C Teng

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
JAMA Dermatology|October 17, 2018
Management of Complex Arteriovenous Malformations Using a Novel Combination Therapeutic AlgorithmMalcolm Pyles Chelliah, Huy M Do, Zachary Zinn, et al.
Dermatology and Therapy|May 11, 2023
Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL StudyKalyani Marathe, Joyce M C Teng, Scott Guenthner, et al.
Clinical and Experimental Dermatology|February 16, 2023
Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosisDedee F Murrell, Joyce M C Teng, Scott Guenthner, et al.
Clinical and Experimental Dermatology|March 17, 2023
Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL studyChristopher G Bunick, Joyce M C Teng, Scott Guenthner, et al.
American Journal of Medical Genetics. Part A|March 13, 2016
RASA1 somatic mutation and variable expressivity in capillary malformation/arteriovenous malformation (CM/AVM) syndromeColleen F Macmurdo, Whitney Wooderchak-Donahue, Pinar Bayrak-Toydemir, et al.
JAMA Dermatology|July 17, 2014
Dermatologic and dental aspects of the 2012 International Tuberous Sclerosis Complex Consensus StatementsJoyce M C Teng, Edward W Cowen, Mari Wataya-Kaneda, et al.
British Journal of Clinical Pharmacology|December 17, 2025
Maximal use of 0.05% topical isotretinoin in patients with congenital ichthyosis results in low systemic exposureHolm Schneider, Christopher G Bunick, Kathrin Hillmann, et al.
Journal of Cutaneous Pathology|October 6, 2021
Next-generation sequencing confirms T-cell clonality in a subset of pediatric pityriasis lichenoidesShyam S Raghavan, Jennifer Y Wang, Alejandro A Gru, et al.
Nature Methods|April 12, 2011
Chemically defined conditions for human iPSC derivation and cultureGuokai Chen, Daniel R Gulbranson, Zhonggang Hou, et al.
The British Journal of Dermatology|May 1, 2025
Nonsyndromic epidermal differentiation disorders: New classification and nomenclature based on disease-associated genes leading to targeted therapyMasashi Akiyama, Keith Choate, Angela Hernandez-Martin, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
JAMA Dermatology|October 17, 2018
Management of Complex Arteriovenous Malformations Using a Novel Combination Therapeutic AlgorithmMalcolm Pyles Chelliah, Huy M Do, Zachary Zinn, et al.
Dermatology and Therapy|May 11, 2023
Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL StudyKalyani Marathe, Joyce M C Teng, Scott Guenthner, et al.
Clinical and Experimental Dermatology|February 16, 2023
Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosisDedee F Murrell, Joyce M C Teng, Scott Guenthner, et al.
Clinical and Experimental Dermatology|March 17, 2023
Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL studyChristopher G Bunick, Joyce M C Teng, Scott Guenthner, et al.
American Journal of Medical Genetics. Part A|March 13, 2016
RASA1 somatic mutation and variable expressivity in capillary malformation/arteriovenous malformation (CM/AVM) syndromeColleen F Macmurdo, Whitney Wooderchak-Donahue, Pinar Bayrak-Toydemir, et al.
JAMA Dermatology|July 17, 2014
Dermatologic and dental aspects of the 2012 International Tuberous Sclerosis Complex Consensus StatementsJoyce M C Teng, Edward W Cowen, Mari Wataya-Kaneda, et al.
British Journal of Clinical Pharmacology|December 17, 2025
Maximal use of 0.05% topical isotretinoin in patients with congenital ichthyosis results in low systemic exposureHolm Schneider, Christopher G Bunick, Kathrin Hillmann, et al.
Journal of Cutaneous Pathology|October 6, 2021
Next-generation sequencing confirms T-cell clonality in a subset of pediatric pityriasis lichenoidesShyam S Raghavan, Jennifer Y Wang, Alejandro A Gru, et al.
Nature Methods|April 12, 2011
Chemically defined conditions for human iPSC derivation and cultureGuokai Chen, Daniel R Gulbranson, Zhonggang Hou, et al.
The British Journal of Dermatology|May 1, 2025
Nonsyndromic epidermal differentiation disorders: New classification and nomenclature based on disease-associated genes leading to targeted therapyMasashi Akiyama, Keith Choate, Angela Hernandez-Martin, et al.
Pageof 5